During the UKPDS trial, there was a 16% reduction in cardiovascular events (combined fatal or nonfatal MI and sudden death) in the intensive glycemic control arm that did not reach statistical significance ( P = 0.052), and there was no suggestion of benefit on other CVD outcomes such as stroke.
1
0.0520
0.0520